Loading
Loading
Review of Case Materials
Reviews records, documents, testimony, data, and other relevant materials and consults with counsel regarding technical issues related to the matter.
Provide Expert Analysis
Applies specialized knowledge and experience to evaluate the technical or professional issues involved.
Form Expert Opinions
Develops independent, supportable opinions based on the available evidence and relevant standards.
Prepare Expert Reports
Showing Results 0 of 0
No. CT, PET, or other imaging may identify a pulmonary nodule or mass with features that raise concern for malignancy, but suspicious imaging does not by itself provide a pathological diagnosis of lung cancer. Many pulmonary nodules are benign. Bronchoscopy, needle biopsy, surgical sampling, or another tissue-sampling method may be used when pathological confirmation and tumor classification are needed.
Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) differ in biological behavior, staging, and treatment. SCLC tends to spread early and is commonly treated with systemic therapy and radiation, with immunotherapy incorporated in selected treatment settings and surgery reserved for a small group of patients with very limited disease. NSCLC includes several histological types and may be treated with surgery, radiation, chemotherapy, targeted therapy, immunotherapy, or combinations of these approaches depending on stage, tumor characteristics, and patient factors.
Biomarker testing is particularly important in non-small cell lung cancer and can influence treatment at several stages of disease. Tumor testing may identify genomic alterations associated with targeted therapies, while biomarkers such as PD-L1 expression can help guide the use of certain immunotherapies. The clinical significance of a result depends on the histological type, stage, specific biomarker, testing method, and available treatment options, so not every detected alteration changes management.
Surgical treatment depends on the cancer type and stage, whether the tumor can be completely resected, lymph-node or distant spread, tumor location, pulmonary reserve, cardiovascular and overall medical condition, and other patient-specific factors. Surgery is a major treatment option for many localized non-small cell lung cancers and selected more advanced resectable tumors as part of multimodality treatment. Radiation or systemic therapy may be used when the disease is unresectable or the patient cannot safely undergo an operation.
Prepares clear, well-supported expert reports outlining methodology, analysis, findings, and opinions.
Provide Deposition Testimony
Explains findings and opinions under oath and responds to questioning during deposition testimony.
Testify in Court
Presents specialized findings and opinions clearly to judges, juries, arbitrators, or other decision-makers.
No. Both non-small cell and small cell lung cancers can recur after appropriately selected treatment. The clinical significance of recurrence should be considered with the original histology and stage, lymph-node and metastatic findings, molecular features when relevant, treatments received, response, surveillance history, and the location and characteristics of recurrent disease. Recurrence may change the subsequent treatment plan without establishing by itself that the earlier care was inappropriate.
